REGN13335 for Pulmonary Arterial Hypertension

(ILLUMINATE Trial)

This trial tests an experimental drug called REGN13335 to determine its safety and effectiveness for individuals with Pulmonary Arterial Hypertension (PAH), a condition that causes high blood pressure in the lungs. Researchers aim to identify potential side effects, understand how the body processes the drug, and assess whether the body produces antibodies that could impact its effectiveness. Participants must have a PAH diagnosis, exhibit noticeable symptoms affecting daily activities, and currently take other PAH medications. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial does not require you to stop taking your current PAH medications. In fact, you need to be on a stable dose of your existing PAH treatment to participate.

Earlier studies tested REGN13335 in adults with pulmonary arterial hypertension (PAH) to assess its safety alongside other PAH medications. Some participants experienced side effects, but overall, the treatment was generally well-tolerated. The available data reported no serious side effects. Researchers also measured the levels of REGN13335 in the blood and monitored for antibody production against it. These assessments help ensure the treatment's effectiveness and safety. While ongoing studies will provide more information, early results suggest that REGN13335 is safe for further testing in people with PAH.¹²³⁴⁵

Unlike the standard treatments for pulmonary arterial hypertension, which often include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin analogs, REGN13335 works by a different mechanism. This investigational treatment is designed to target specific pathways involved in the disease, potentially offering a new way to manage symptoms and improve patient outcomes. Researchers are excited about REGN13335 because it could provide an alternative for patients who don't respond well to existing therapies, offering hope for more personalized and effective treatment options.

Research has shown that REGN13335 could be a promising treatment for Pulmonary Arterial Hypertension (PAH). Studies have found that this drug blocks a protein called PDGF-B, which supports the growth and health of blood vessels. By inhibiting this protein, REGN13335 may help lower pressure in the lung arteries. In animal studies, it improved heart function and reduced disease symptoms. Although research in humans is ongoing, these early results suggest it could offer a new treatment option for PAH without relying on widening blood vessels. Participants in this trial will join different arms, including experimental arms and a placebo comparator, to further evaluate the effectiveness and safety of REGN13335.¹²³⁴⁵